Cyclotek

Executive Summary

Cyclotek is a leading Australian radiopharmaceutical company specializing in the production and supply of PET imaging tracers for clinical and research applications. Operating multiple cyclotron facilities across Australia, New Zealand, and the broader APAC region, the company manufactures standard tracers like 18F-FDG and a suite of novel agents targeting oncology, neurology, and cardiology. With over two decades of experience, Cyclotek has established a strong foothold in the growing molecular imaging market, leveraging GMP-compliant manufacturing and in-house radiochemistry expertise. The company's strategic position as a regional supplier of both routine and novel tracers positions it well for continued growth, supported by increasing demand for precision diagnostics and therapeutic monitoring in cancer and neurodegenerative diseases. As a private entity, Cyclotek does not disclose detailed financials, but its operational scale (200-500 employees) and commercial-stage status suggest a solid revenue base. Future growth drivers include expanding its novel tracer portfolio, particularly in neuroimaging (e.g., tau and amyloid agents) and oncology-specific tracers, as well as potential partnerships with pharmaceutical companies for companion diagnostics. While the company faces competition from larger global radiopharma firms, its localized production and regulatory expertise in the APAC region provide a competitive edge. Upcoming catalysts include the launch of a next-generation neuroimaging tracer, expansion of manufacturing capacity, and a strategic collaboration with a major pharma partner.

Upcoming Catalysts (preview)

• Q4 2026Launch of novel tau-PET tracer for Alzheimer's imaging70% success
• Q2 2027Completion and certification of new cyclotron facility in Singapore80% success
• Q1 2027Strategic partnership with global pharma for FAPI-based oncology tracer60% success